AIM ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules

§ 01 Executive Snapshot

• What: AIM ImmunoTech has announced a financing round totaling approximately $2.65 million through a registered direct offering and concurrent private placement.
• Who: AIM ImmunoTech Inc. (NYSE American: AIM) and Ladenburg Thalmann & Co. Inc. as the exclusive placement agent.
• Why it matters: This financing is intended to support the company's clinical trial activities and manufacturing of drug supply, critical for its ongoing and planned developments in cancer and viral disease therapeutics.

§ 02 Key Developments

• The offering will close on or about June 10, 2026, subject to customary closing conditions.
• AIM will issue 2,554,119 shares of common stock at a price of $0.5189 per share in the registered direct offering.
• In the private placement, AIM will also issue 2,554,119 unregistered shares and Class J Warrants to purchase up to 10,216,476 shares of common stock with an exercise price of $0.5189 per share.

§ 03 Strategic Context

• AIM ImmunoTech focuses on developing therapeutics for cancers, immune disorders, and viral diseases, including its lead product Ampligen®, which is currently in clinical trials.
• The financing comes at a critical time as the company prepares for Phase 3 clinical trials and seeks to enhance its research capabilities.

§ 04 Strategic Implications

• The immediate consequence of this funding is the ability to further advance clinical trials, potentially leading to significant breakthroughs in treatment options for serious health conditions.
• Long-term, successful clinical outcomes could enhance AIM's market position and attract additional investment or partnerships in the biotech sector.

§ 05 Risks & Constraints

• Potential risks include the ability to satisfy closing conditions and uncertainties related to the success of clinical trials and regulatory approvals.
• There may also be competition in the biotech space, which could impact AIM's market opportunities and funding access.

§ 06 Watchlist / Forward Signals

• Key milestones to watch include the anticipated closing of the offering on June 10, 2026, and the progress of clinical trials for Ampligen®.
• Future developments that signal success will include positive results from clinical trials and potential partnerships or collaborations that could arise post-funding.